Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 302
  • Print this page
  • Email this page

 
Table of Contents
PERSPECTIVE
Year : 2023  |  Volume : 16  |  Issue : 1  |  Page : 1-2

Time to stimulate Plasmodium vivax research in India: A way forward


1 Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura, UP, India
2 ICMR-National Institute of Malaria Research, Dwarka, 110077, New Delhi, India

Date of Submission30-Nov-2022
Date of Decision15-Dec-2022
Date of Acceptance18-Jan-2023
Date of Web Publication25-Jan-2023

Correspondence Address:
Praveen Kumar Bharti
ICMR-National Institute of Malaria Research, Dwarka, 110077, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.368016

Rights and Permissions

How to cite this article:
Gupta H, Nema S, Bharti PK. Time to stimulate Plasmodium vivax research in India: A way forward. Asian Pac J Trop Med 2023;16:1-2

How to cite this URL:
Gupta H, Nema S, Bharti PK. Time to stimulate Plasmodium vivax research in India: A way forward. Asian Pac J Trop Med [serial online] 2023 [cited 2023 Feb 7];16:1-2. Available from: https://www.apjtm.org/text.asp?2023/16/1/1/368016

India bears the largest Plasmodium (P.) vivax (Pv) malaria burden and contributes 48% of Pv cases globally[1]. The efforts of government and private bodies to control malaria have successfully reduced the number of Plasmodium falciparum(Pf) malaria cases in several countries, including India. However, there has been a consistent increase in Pv cases, particularly in regions where both parasites coexist. Consequently, Pv presents an obstacle to elimination and is more challenging to eradicate than Pf for several reasons: 1) Pv has a wider geographic range since it can thrive in colder climes; 2) vector control methods are less effective because Pv parasite-carrying mosquitoes bite early, rest outdoors, and consume blood outdoors; 3) current diagnostic tools cannot detect low-density Pv infections and dormant hypnozoites; 4) hypnozoites can trigger multiple malaria episodes, and Pv gametocytes are produced earlier, enabling transmission even before clinical symptoms; and 5) 14-day primaquine is the only effective drug against hypnozoites; however, it can cause life-threatening haemolytic anaemia in individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency, which makes primaquine treatment difficult[2].

Pv has an evolutionary path distinct from Pf (which causes a lethal form of malaria), being closely associated with P. cynomolgi which is responsible for infection in Asian macaque monkeys[3]. Due to this evolutionary path, Pv shows unique biological features such as 1) preference to invade reticulocytes; 2) earlier production of gametocytes; 3) formation of dormant hypnozoites[4]. Pv also has unique morphological features, including 1) the small dark granules in the reticulocyte cytoplasm, known as Schüffner’s dots; 2) the sexual stage of Pv parasites has a round shape similar to the asexual stages[4]. The biological basis for the development of falciparum severe malaria via sequestration of P. falciparum-infected erythrocytes in the host vital organs, and involvement of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) in promoting the cytoadherence of infected erythrocytes in severe malaria are well described. In the case of Pv infections, a group of variable proteins expressed on the reticulocyte surface are suggested to have a role in mediating the cytoadherence of infected erythrocytes to endothelial cells and the placenta[4]. Another key feature of Pv biology is the hypnozoites which are metabolically active and remain dormant for weeks to months before reactivating. Furthermore, it is evident that relapses in Pv infections are due to hypnozoites[4].

Pv infection has been perceived as benign until recently, despite life-threatening complications reported[4]. Patients with Pv infection were found positive for both asexual and sexual parasites in the peripheral circulation, enhancing community transmission. Besides, Pv sporozoites develop faster in the mosquito midgut compared to those with falciparum. Pv malaria in pregnancy is also associated with maternal anaemia and low birthweight neonates[5]. In developing countries where co-infections are frequent, Pv hypnozoites can be activated by systemic bacterial and parasitic infections, which is the most common cause of relapse in Pv patients. However, Pf continues to be the main area of interest for most malaria researchers. We conducted a 20-year PubMed search on January 08, 2023, using the terms "India" and either "Plasmodium falciparum" or "Plasmodium vivax" to determine the extent of Pv research in India (2002-2022). This search turned up 3515 and 1231 articles on Pf and Pv in India, respectively, which emphasises the need for researchers, funding agencies, and malaria elimination programmes to invest in Pvresearch to develop 1) tools that can detect hypnozoites and 2) a short and effective treatment against hypnozoites.

Pv only infects reticulocytes that account for 1%-2% of red blood cells in adult peripheral blood[6]. These cells are fragile, have rapid maturation, and complicated techniques are needed to get enriched samples. Therefore, it is challenging to maintain a reliable long-term Pv culture to facilitate needed research. Hence, the P. knowlesi culture as a vivax model has been used to understand the unique biology of Pv. Moreover, to detect and treat Pv hypnozoites, microRNAs (miRNAs) can be an excellent approach. Studies have shown the association of miR-3158-3p with severe Pf malaria in Indian adults and Mozambican children, highlighting a promising biomarker candidate for diagnosis across age groups and geographical regions[7]. Similarly, let-7b-5p, miR-16, 24, 28-3p, 144, 150, 191, 194-5p, 221/222, 378-5p, 451, 520f-3p, 3667-5p, and 7977 miRNAs were found associated with Pv infection[7]. However, they require further validation in large sample sizes before developing multiplex miRNA-based assays to detect low-density peripheral Pv infections and hypnozoites. In addition, miRNA mimics and inhibitors (antimiRs) are two categories of miRNA-based therapeutics[7]. The miR-34 mimic, MRX34, has reached Phase I clinical trials for treating cancer. Similarly, an antimiR against miR-122 has reached Phase II trials for treating patients with the hepatitis C virus. Based on these promising results, Pv-associated miRNAs (mentioned above) can also be investigated for their potential to treat hypnozoites.

Lessons from countries such as Iran and Sri Lanka as well as China’s successful malaria elimination programs can be adapted to overcome Pv cases in India[8]. Chinese malaria elimination programs mainly targeted three components: the source of infection, individuals susceptible to infection, and the mosquito vectors[9]. Mass drug administration with different antimalarials was used during and between malaria seasons to clear the hypnozoite reservoir and protect susceptible individuals. This led to a reduction from 13 million malaria cases to only 1 million. Elimination was achieved in regions where Pv was transmitted by Anopheles (An.) sinensis. For vector control, indoor residual spraying was of limited effectiveness. However, a field trial with insecticide-treated nets demonstrated a significant decrease in the indoor vector density of An. sinensisand An. lesteri. Furthermore, the use of new irrigation schemes to improve agriculture productivity in China led to a substantial reduction in malaria morbidity[10]. Similarly, Sri Lanka’s national strategy for malaria elimination was based, broadly, on the World Health Organization guidelines for elimination, which included targeted vector control, intensified case surveillance and radical treatment, and case investigation and response[11].

This article provides a basis for further Pv research to eliminate malaria in India. Development of new tools for early Pv diagnosis and case management as per the local needs should be a prerequisite along with robust healthcare systems. The elimination of malaria will be facilitated by improved public-private partnerships, greater clarity in research, and strong political commitment. The Global Malaria Eradication Programme of the 1960s was extremely successful in eradicating malaria from several parts of the world, but it failed to accomplish its goal in India due to technical, financial, and operational negligence. Reinforcing the goal of eliminating malaria from India offers a chance to take lessons from the past and make malaria-free India.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

The authors received no extramural funding for the study.

Authors’ contributions

HG and SN did the literature search; HG and SN drafted the manuscript; PKB gave intellectual comments and reviewed the final version.

 
  References Top

1.
World Health Organization. World malaria report 2021. [Online]. Available from: https://www.who.int/publications-detail-redirect/9789240040496. [Accessed on 28 September 2022].  Back to cited text no. 1
    
2.
Nema S, Ghanghoria P, Bharti PK. Malaria elimination in India: Bridging the gap between control and elimination. Indian Pediatr 2020; 57(7): 613-617.  Back to cited text no. 2
    
3.
Bourgard C, Albrecht L, Kayano ACAV, Sunnerhagen P, Costa FTM. Plasmodium vivax biology: Insights provided by genomics, transcriptomics and proteomics. Front Cell Infect Microbiol 2018; 8: 34.  Back to cited text no. 3
    
4.
Adams JH, Mueller I. The biology of Plasmodium vivax. Cold Spring Harb Perspect Med 2017; 7(9): a025585.  Back to cited text no. 4
    
5.
Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet Lond Engl1999; 354(9178): 546-549.  Back to cited text no. 5
    
6.
Bermúdez M, Moreno-Pérez DA, Arévalo-Pinzón G, Curtidor H, Patarroyo MA. Plasmodium vivax in vitro continuous culture: The spoke in the wheel. Malar J 2018; 17(1): 301.  Back to cited text no. 6
    
7.
Gupta H, Wassmer SC. Harnessing the potential of miRNAs in malaria diagnostic and prevention. Front Cell Infect Microbiol 2021; 11: 793954.  Back to cited text no. 7
    
8.
Moqarabzadeh V, Enayati AA, Raeisi A, Nikpour F, Charati JY. Provincial clustering of malaria in Iran between 2005 and 2014. Asian Pac J Trop Med 2020; 13: 162-168.  Back to cited text no. 8
    
9.
Li X, Tu Y, Tang L, Gao Q, Alonso PL. The role of research in China’s successful elimination of malaria. Nat Med 2022; 28(7): 1336-1338.  Back to cited text no. 9
    
10.
Odufuwa OG, Moore SJ, Mboma ZM, Mbuba E, Muganga JB, Moore J, et al. Insecticide-treated eave nets and window screens for malaria control in Chalinze district, Tanzania: A study protocol for a household randomised control trial. Trials 2022; 23(1): 578.  Back to cited text no. 10
    
11.
Premaratne R, Wickremasinghe R, Ranaweera D, de AW Gunasekera WMKT, Hevawitharana M, Pieris L, et al. Technical and operational underpinnings of malaria elimination from Sri Lanka. Malar J 2019; 18(1): 256.  Back to cited text no. 11
    

Publisher’s note The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed849    
    Printed10    
    Emailed0    
    PDF Downloaded113    
    Comments [Add]    

Recommend this journal